JEJennifer L Evans

Jennifer L Evans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jennifer L Evans has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Alice Asher

    Department of Community Health Systems, School of Nursing, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA 94122, USA

    1 shared publication
  • Alya Briceno

    Department of Epidemiology and Biostatistics and Global Health Science, University of California San Francisco, 50 Beale Street, Suite 1200, San Francisco, CA 94105, USA

    1 shared publication
  • Benjamin Hayes

    Department of Epidemiology and Biostatistics and Global Health Science, University of California San Francisco, 50 Beale Street, Suite 1200, San Francisco, CA 94105, USA

    1 shared publication
  • Judith A. Hahn

    Department of Medicine, University of California San Francisco, San Francisco, USA

    1 shared publication
  • Kimberly Page

    Department of Internal Medicine, University of New Mexico Health Sciences Center, University of New Mexico, MSC 10 5550, Albuquerque, NM 87131, USA

    1 shared publication
  • Michelle Yu

    Department of Epidemiology and Biostatistics and Global Health Science, University of California San Francisco, 50 Beale Street, Suite 1200, San Francisco, CA 94105, USA

    1 shared publication

Latest Publications

  • Open Access

    Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs

    by Benjamin Hayes, Alya Briceno, Alice Asher, Michelle Yu, Jennifer L Evans, Judith A Hahn, Kimberly Page

    People who inject drugs (PWID) are at highest risk for hepatitis C virus (HCV) infection, yet many remain unaware of their infection status. New anti-HCV rapid testing has high potential to impact this. Young adult (<30 years) active PWID were offered either the rapid OraQuick® or standard anti-HCV test involving phlebotomy, then asked to complete a short questionnaire about testing perceptions and preferences. Sample characteristics, service utilization, and injection risk exposures are assessed with the HCV testing choice as the outcome, testing preferences, and reasons for preference. Of 129 participants: 82.9% (n = 107) chose the rapid test. There were no significant differences between those who chose rapid vs. standard testing. A majority (60.2%) chose the rapid test for quick results; most (60.9%) felt the rapid test was accurate, and less painful (53.3%) than the tests involving venipuncture. OraQuick® anti-HCV rapid test was widely accepted among young PWID. Our results substantiate the valuable potential of anti-HCV rapid testing for HCV screening in this high risk population.